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Abstract
This report presents the efficacy and safety of insulin degludec/liraglutide (IDegLira)
versus insulin glargine 100 units/mL (IGlar U100) as initial injectable therapy at
26 weeks in the 104-week DUAL VIII durability trial (NCT02501161). Participants
(N = 1012) with type 2 diabetes (T2D) uncontrolled on oral antidiabetic drugs (OADs)
were randomized 1:1 to open-label IDegLira or IGlar U100. Visits were scheduled at
weeks 1, 2, 4 and 12, and every 3 months thereafter. After 26 weeks, glycated
haemoglobin (HbA1c) reductions were greater with IDegLira versus IGlar U100
(−21.5 vs. –16.4 mmol/mol [−2.0 vs. –1.5%]), as was the percentage of participants
achieving HbA1c <53 mmol/mol (78.7% vs. 55.7%) and HbA1c targets without
weight gain and/or hypoglycaemia. Estimated treatment differences for insulin dose
(−13.01 U) and body weight change (−1.57 kg) significantly favoured IDegLira. The
hypoglycaemia rate was 44% lower with IDegLira versus IGlar U100. Safety results
were similar. In a trial resembling clinical practice, more participants receiving
IDegLira than IGlar U100 met treatment targets, supporting use of IDegLira as an ini-
tial injectable therapy for people with T2D uncontrolled on OADs and eligible for
insulin initiation.
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1 | INTRODUCTION
Because of its progressive nature, people with type 2 diabetes (T2D)
often eventually require injectable therapies to achieve glycaemic
control. The current guidelines for management of T2D recommend
injectable therapies when oral antidiabetic drugs (OADs) have failed
to achieve control, with glucagon-like peptide-1 receptor agonists
(GLP-1RAs) now being the recommended first choice of injectable
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drug in most cases.1,2 Although GLP-1RAs are recommended, basal
insulin currently remains the most widely used first injectable
therapy,3-5 particularly in people with high glycated haemoglobin
(HbA1c) levels.1,2 A fixed-ratio combination therapy of basal insulin
and GLP-1RAs, such as insulin degludec/liraglutide (IDegLira), is a pos-
sible alternative treatment choice for an initial injectable therapy,
based on evidence from the DUAL clinical development
programme.6-10
In the 104-week DUAL VIII trial, which had a schedule designed
to resemble recommended clinical practice, treatment with IDegLira
resulted in a significantly longer time before treatment intensification
was needed compared with insulin glargine 100 units/mL (IGlar U100;
median duration >2 years with IDegLira and ~1 year for IGlar
U100).11 The first 26 weeks of this trial were aimed at optimizing
titration of the randomized injectable, with the goal of reaching
HbA1c <53 mmol/mol (<7.0%). Throughout DUAL VIII, clinic visits
were scheduled less frequently than typical treat-to-target diabetes
trials, and titration was guided entirely by the investigator, with no
external monitoring beyond trial site staff.
We report the prespecified efficacy and safety outcomes at
week 26 to assess whether previously seen efficacy benefits of initi-
ating IDegLira compared with IGlar U100 were observed in the ini-
tial titration and dose optimization within the first 26 weeks, in a
trial with a visit frequency resembling recommended clinical practice
in a population of participants with T2D inadequately controlled
with OADs.
2 | MATERIALS AND METHODS
2.1 | Trial design
DUAL VIII was a phase 3b, multinational, open-label, two-arm parallel,
104-week randomized trial (NCT02501161) consisting of a 2-week
screening period, a 104-week treatment period and two follow-up
safety assessments (Figure S1). Three clinic visits (weeks 2, 4 and 12)
and one telephone contact were scheduled between baseline and
week 12, to guide insulin-naïve participants on how to titrate the trial
drug, with visits every 3 months thereafter, to assess the need for
treatment intensification, thereby mirroring recommendations in the
current guidelines for management of T2D.1,2 Unscheduled visits
were performed if required, specifically if an adverse event
(AE) needed further attention or additional laboratory samples/testing
were needed.
DUAL VIII was conducted in accordance with the International
Conference on Harmonization Guideline for Good Clinical Practice
and the Declaration of Helsinki.12,13 Informed consent was obtained
before any trial-related activities.
2.2 | Participants
Inclusion and exclusion criteria have been published previously.11
2.3 | Procedures/interventions
Participants were randomized 1:1 to receive either IDegLira in a 3-mL
prefilled PDS290 pen or IGlar U100 in a 3-mL prefilled Solostar® pen,
both administered once daily by subcutaneous injection, in combina-
tion with OAD(s) using an interactive web response system.
Both treatments, IDegLira (1 U = 1 U degludec + 0.036 mg
liraglutide) and IGlar U100, were initiated at 10 U. The maximum dose
of IDegLira was 50 U and there was no maximum dose for IGlar U100.
Investigators were guided to titrate twice weekly to a fasting plasma
glucose (FPG) target of 4.0 to 5.0 mmol/L (72–90 mg/dL); adjustments
were made in increments of 2 U. Full details of the titration of IDegLira
and IGlar U100 can be found in the Supporting Information (Table S1).
2.4 | Prespecified outcome measures
The present report details safety and efficacy data up to week 26 only;
endpoints derived from the entire 104-week treatment period have been
reported previously.11 Supportive secondary efficacy endpoints included
change from baseline in HbA1c and body weight after 26 weeks of treat-
ment, daily insulin dose at week 26, proportion of participants achieving
HbA1c targets of <53 mmol/mol (<7.0%) and ≤48 mmol/mol (≤6.5%),
and the composite endpoint of HbA1c targets without hypoglycaemia
and/or without weight gain by week 26. For the composite endpoints, it
was prespecified that only hypoglycaemic events during the last
12 weeks of treatment leading up to week 26 would be assessed, in
keeping with previous DUAL trials. Safety endpoints included the num-
ber of treatment-emergent severe (requiring third-party assistance) or
blood glucose-confirmed (<3.1 mmol/L [<56 mg/dL]) symptomatic hyp-
oglycaemic events during 26 weeks of treatment, and the number of
treatment-emergent AEs during 26 weeks of treatment.
2.5 | Statistical analyses
Full statistical analysis details can be found in the Supporting Information.
3 | RESULTS
In total, 506 participants were randomized to each treatment arm and
506/504 participants received at least one dose of IDegLira/IGlar
U100, respectively. Baseline characteristics were well matched.11
3.1 | Key efficacy and safety endpoints
3.1.1 | Glycaemic control
Mean change from baseline (least squares [LS] mean) in HbA1c was
−21.5 mmol/mol (−2.0%) with IDegLira and −16.4 mmol/mol (−1.5%)
with IGlar U100 after 26 weeks of treatment, corresponding to an
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estimated treatment difference (ETD) of −5.12 mmol/mol (95% confi-
dence interval [CI] –6.33 to −3.91; −0.47% [95% CI –0.58 to −0.36];
P < 0.0001 [Figure 1]).
3.1.2 | Other key efficacy endpoints
A greater proportion of participants treated with IDegLira versus IGlar
U100 achieved the composite endpoints of HbA1c <53 mmol/mol
(<7.0%) without hypoglycaemia (71.3 vs. 44.9%), HbA1c <53 mmol/
mol (<7.0%) without weight gain (38.5 vs. 15.4%) and HbA1c
<53 mmol/mol (<7.0%) without hypoglycaemia and weight gain (35.2
vs. 13.6%). The odds of participants achieving HbA1c targets of
<53 mmol/mol (<7.0%) and ≤48 mmol/mol (≤6.5%) were significantly
greater with IDegLira compared with IGlar U100, as were the odds of
achieving the composite endpoints of HbA1c targets without weight
gain and/or hypoglycaemia, after 26 weeks of treatment (Figure 2).
Mean change from baseline (LS mean) in body weight was 0.5 kg with
IDegLira and 2.1 kg with IGlar U100 (ETD −1.57 kg [95% CI –2.00 to
−1.13]; P < 0.0001 [Figure S2]). Mean daily insulin dose (LS mean) at
week 26 was lower with IDegLira (35.4 U) compared with IGlar U100
(48.4 U; ETD –13.01 U [95% CI –15.03 to −10.99]; P <0.0001).
Over 26 weeks, the rate of severe or blood glucose-confirmed
symptomatic hypoglycaemia was significantly lower with IDegLira
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versus IGlar U100 (LS mean 53.7 vs. 95.3 events/100 participant-
years of exposure [PYE], rate ratio 0.56 [95% CI 0.39 to 0.82];
P = 0.0023). The mean cumulative number of severe or blood
glucose-confirmed symptomatic hypoglycaemic events over time is
shown in Figure S3. Rates of nocturnal severe or blood glucose-
confirmed symptomatic hypoglycaemia (occurring between 12:01 and
5:59 AM [both inclusive]) were also significantly lower with IDegLira
versus IGlar U100 (LS mean 8.8 vs. 19.5 events/100 PYE, rate ratio
0.45 [95% CI 0.24 to 0.83]; P = 0.0102).
3.1.3 | Adverse events
Rates of AEs were 291.0 events/100 PYE with IDegLira and 257.5
events/100 PYE with IGlar U100. The majority of AEs were non-seri-
ous, mild in severity and unlikely to be related to trial products, as
judged by the investigator. Two fatal events occurred during the first
26 weeks; both were in the IGlar U100 treatment arm and considered
unlikely to be related to trial product.
4 | DISCUSSION
The present analysis of the DUAL VIII trial demonstrated that, after
the initial 26 weeks, more participants achieved clinically relevant
composite endpoints (HbA1c targets without weight gain and/or
hypoglycaemia) with IDegLira than with IGlar U100.
During the DUAL VIII trial, titration was guided entirely by the
investigator, with no external monitoring beyond trial site staff, with
one scheduled telephone contact and visits at weeks 1, 2, 4 and
12, and every 3 months thereafter, mirroring recommendations in the
current guidelines for management of T2D.1,2,11
Attainment of treatment targets at week 26 in the DUAL VIII trial
was consistent with previous DUAL trials. In trials conducted in post-
OAD populations, more IDegLira-treated participants achieved HbA1c
<53 mmol/mol (<7.0%) without weight gain and without
hypoglycaemia compared with degludec alone or IGlar U100.6,7 These
trials illustrate the advantages of a combination of liraglutide and
degludec over basal insulin alone. The improved efficacy probably
reflects the complementary action of the two components, with
degludec reducing FPG and HbA1c, and liraglutide reducing both FPG
and postprandial glucose control in a glucose-dependent manner. In
addition, the mechanism of action of liraglutide addresses multiple
aspects of the underlying pathogenic abnormalities in T2D (eg, declin-
ing β-cell function, excessive secretion of glucagon from pancreatic α
cells, lipotoxicity, and insulin resistance in liver and peripheral tissues)
and has been shown to lower the risk of cardiovascular disease and
mortality in individuals at increased risk.14,15 The beneficial effects
with respect to weight and hypoglycaemia with IDegLira versus basal
insulin are likely to predominantly be a result of the lower insulin
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requirement made possible by the liraglutide component, but may also
be partly attributable to the reduced rates of hypoglycaemia reported
for degludec versus IGlar U100.16-18
Our results are consistent with the demonstrated insulin-sparing
effects of IDegLira compared with IGlar U100.7 End-of-trial insulin
dose was also significantly lower with IDegLira versus degludec in
insulin-naïve participants during the 26-week treatment in DUAL I
(wherein IDegLira demonstrated non-inferiority to degludec for
change in HbA1c). The DUAL I trial represented a typical treat-to-
target diabetes trial, with guidance on titration given during
18 telephone contacts and 11 scheduled site visits, with any significant
deviations from the titration algorithm being addressed by an external
titration committee.6 That insulin doses at week 26 were only slightly
lower (IDegLira: 35 U; IGlar U100: 48 U) than in DUAL I (IDegLira:
38 U; degludec: 53 U) suggests that, while still under clinical trial con-
ditions, the lower frequency of clinic visits is sufficient to guide appro-
priate titration.6 However, comparisons should be made cautiously, as
the participants in DUAL VIII received more OADs and had a longer
duration of diabetes compared with participants in DUAL I.6
The results also build on the available safety data for IDegLira,
with no unexpected safety findings and low overall rates of AEs.9 Full
safety results of the 104-week trial have been reported previously.11
The present trial did not include a treatment arm randomizing
participants to receive GLP-1RA therapy alone, which would be an
alternative initial injectable therapy for people uncontrolled on OADs.
Basal insulin was chosen as a comparator as it is the most widely used
injectable antidiabetic therapy. The major strength of this study was
that the trial design mirrored clinical practice, with investigator-guided
titration. With this design we still showed attainment of treatment
targets without the visit frequency and strict titration protocol of typi-
cal treat-to-target trials, in a trial population that reflects people with
T2D eligible for basal insulin initiation.
In conclusion, after 26 weeks of treatment in a trial design resem-
bling recommended clinical practice, more participants met treatment
targets with IDegLira versus IGlar U100, with a lower insulin dose and
with less hypoglycaemia and weight gain, which supports the use of
IDegLira as a first injectable therapy for people with T2D eligible for
treatment intensification.
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